Abstract
Observational studies and clinical trials have established that lipid disorders (elevated serum total cholesterol [TC], low-density lipoprotein cholesterol [LDLc], or triglycerides [TGs] and reduced serum high-density lipoprotein cholesterol [HDLc]) are independently associated with the risk of coronary heart disease (CHD). Hyperlipidemia was also clearly associated with progression of carotid and peripheral atherosclerosis and intima-media thickness (IMT), a marker of early atherosclerosis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 2001;57(Suppl 2):S35—S44.
Hachinski V, Graffagnino C, Beaudry M, et al. Lipids and stroke: a paradox resolved. Arch Neurol 1996;53:303–308.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7–22.
The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda, MD: National Heart, Lung and Blood Institute, National Institutes of Health, May 2001. NIH Publication 01–3305. (Summary published in JAMA 2001;285(19):2486–2497)
Van Horn L, McDonald A, Peters E, Gernhofer N. Dietary management of cardiovascular disease: a year 2002 perspective. Nutr Clin Care 2001;4:314–331.
Krauss RM, Eckel RH, Howard B, et al. AHA dietary guidelines. Revision 2000: a statement for health care professionals from the nutrition committee of the American Heart Association. Circulation 2000;102;2284–2299.
Kromhout D, Menotti A, Kesteloot H, Sana S. Prevention of coronary heart disease by diet and lifestyle. Evidence from prospective cross-cultural, cohort, and intervention studies. Circulation 2002;105:893–898.
US Department of Agriculture and US Department of Health and Human Services. Nutrition and Your Health: Dietary Guidelines for Americans. 5th ed. Washington, DC: US Department of Agriculture, 2000. Home and Garden Bulletin 232.
Bernini F, Poli A, Paoletti R. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovasc Drugs Then 2001;15:211–218.
Pasternak RC, Smith SC Jr, Bairy-Merz CN, et al. ACC/AHA/NHLBI advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:568–573.
Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med 2001;111:390–400.
Batiste MC, Schaefer EJ. Diagnosis and management of lipoprotein abnormalities. Nutr Clin Care 2002;5:115–123.
Lousberg TR, Denham AM, Rasmussen JR. A comparison of clinical outcome studies among cholesterol-lowering agents. Ann Pharmacother 2001;35:1599–1607.
Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol 2002; 89(Suppl):50C-57C.
Reaven G. Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation 2002;106:286–288.
Goldstein JL, Brown MS. The cholesterol quartet. Science 2000;292:1310–1312.
Rader DJ, Rosas S. Management of selected lipid abnormalities. Hypertriglyceridemia, low HDL cholesterol, lipoprotein(a), in thyroid and renal disease, and posttransplantation. Med Clin North Am 2000;84:43–61.
Jonkers IJAM, Smelt AHM, yen der Laarse A. Hypertriglyceridemia. Associated risks and effect of drug treatment. Am J Cardiovasc Drugs 2001;1:455–466.
Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082–1085.
Luc G, Bard JM, Arveiler D, et al. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis 2002;163:377–384.
Haralampos MJ, Winder AF, Mikhailidis DP. Lipoprotein(a) and stroke. J Clin Pathol 2000;53:487–496.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Topcuoglu, M.A., Buonanno, F.S., Kelly, P.J. (2004). Evaluation and Management of Hyperlipidemia for Stroke Prevention. In: Furie, K.L., Kelly, P.J. (eds) Handbook of Stroke Prevention in Clinical Practice. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-769-7_4
Download citation
DOI: https://doi.org/10.1007/978-1-59259-769-7_4
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9856-1
Online ISBN: 978-1-59259-769-7
eBook Packages: Springer Book Archive